| 11.545 -0.325 (-2.74%) | 09-15 11:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.95  |
1-year : | 16.03 |
| Resists | First : | 12.8 |
Second : | 13.72 |
| Pivot price | 12.54 |
|||
| Supports | First : | 11.31 |
Second : | 9.4 |
| MAs | MA(5) : | 11.82 |
MA(20) : | 12.54 |
| MA(100) : | 13.2 |
MA(250) : | 13.42 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 8 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 28.25 | Low : | 7.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTLA ] has closed below the lower bollinger band by 0.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NTLA ] is to continue within current trading range. It is unclear right now based on current values. 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.14 - 12.22 | 12.22 - 12.29 |
| Low: | 11.46 - 11.56 | 11.56 - 11.66 |
| Close: | 11.71 - 11.87 | 11.87 - 12.02 |
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Mon, 14 Sep 2026
NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects - TradingView
Sun, 13 Sep 2026
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Fri, 11 Sep 2026
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Fri, 04 Sep 2026
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - Intellia Therapeutics
Fri, 04 Sep 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 1.3415e+008 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 45,780 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.144e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 472.2 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 5.951e+007 % |
| Gross Profit (p.s.) | -25.39 |
| Sales Per Share | -30.47 |
| EBITDA (p.s.) | -1.22429e+008 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -347 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.38 |
| Price to Cash Flow | 3.98 |
| Dividend | 0 |
| Forward Dividend | 4.488e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|